In 2022, PreciPoint will commercially launch the iO:M8 ROSE, a globally unique solution for the digitization of intraoperative microscopic assessments during cancer surgeries. These examinations, during which pathologists determine whether sufficient material has been removed from the patient’s body and whether the margins are free of cancer cells, are traditionally performed by specialists being bound to location and time using classic light microscopes for imaging. PreciPoint’s solutions enable entirely new ways of working, allowing significant cost savings and, most importantly, better patient care.  

PreciPoint specializes in the digitization of microscopy and laboratory workflows. The company offers solutions for applications in medicine, research, and education and its devices are used in many laboratories worldwide. It is central to PreciPoint’s philosophy to develop products together with users. Thus, the company works with many respected pathologists in Germany to design products that meet the highest standards while being quick and easy to use. This includes a focus on the development of technologies for Label-Free Diagnostics, where samples can be viewed entirely without expensive and time-consuming sample preparation, as well as the development of product solutions for high-speed applications to help meet the increasing demand in pathology labs.  

Excellent prospects that also convinced the investors: "Since our seed investment in 2019, the team around the two co-founders and managing directors Nicolas Weiss and Dominik Gerber has made enormous progress. Renowned distribution partners could be acquired, new products could be developed and successfully placed on the market. At the same time, the prerequisites were created to quickly scale the company. We firmly believe that PreciPoint, as a ISO13485 certified medical device company, will be able to successfully position its product portfolio on the European and American markets," said Stefan Jahn, Senior Investment Manager at bm|t.